GlassScriptPhysician profile
Sonya B Tatum
NPI 1760755433
$9,145.30
in general payments reported to CMS, 2019-2025
58 companies · $1,357 in 2025
The $1,357 reported for 2025 was more than what 89% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,820 · 2022: $1,894 · 2023: $1,814 · 2024: $1,260 · 2025: $1,357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,265 · Education: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,264.72 |
| Education | $166.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,101.41 | 2021-2025 | |
| Novo Nordisk INC | $739.56 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $547.01 | 2021-2025 | Repatha, Otezla, Evenity |
| Astellas Pharma US INC | $530.91 | 2021-2024 | Veozah, Myrbetriq |
| Lilly USA, LLC | $511.36 | 2021-2025 | Mounjaro, Jardiance, Kisunla |
| Janssen Pharmaceuticals, INC | $504.16 | 2021-2022 | |
| Pfizer INC. | $446.02 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $399.14 | 2021-2025 | Xifaxan, Cycloset |
| Astrazeneca Pharmaceuticals LP | $398.42 | 2021-2025 | Farxiga, Airsupra |
| Otsuka America Pharmaceutical, INC. | $367.58 | 2021-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $364.29 | 2021-2025 | |
| Glaxosmithkline, LLC. | $240.87 | 2021-2024 | Trelegy Ellipta, Arexvy |
| Sumitomo Pharma America, INC. | $239.84 | 2023-2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $212.95 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $199.91 | 2021-2024 | Trintellix |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonya Tatum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.